Alnylam Pharmaceuticals
ALNY
#814
Rank
ยฃ22.69 B
Marketcap
ยฃ169.59
Share price
0.05%
Change (1 day)
-49.93%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Cash on Hand

Cash on Hand as of June 2026 : ยฃ2.49 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company has ยฃ2.49 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Alnylam Pharmaceuticals - Cash on Hand chart (from 2003 to 2026)

Cash on Hand by year

Year Cash on Hand Change
2025-12-31ยฃ2.15 B0.58%
2024-12-31ยฃ2.14 B12.14%
2023-12-31ยฃ1.91 B5.66%
2022-12-31ยฃ1.81 B0.44%
2021-12-31ยฃ1.80 B31.21%
2020-12-31ยฃ1.37 B17.38%
2019-12-31ยฃ1.17 B37.16%
2018-12-31ยฃ0.85 B-31.72%
2017-12-31ยฃ1.25 B146.25%
2016-12-31ยฃ0.50 B-30.33%
2015-12-31ยฃ0.72 B62.94%
2014-12-31ยฃ0.44 B200.21%
2013-12-31ยฃ0.14 B96.17%
2012-12-31ยฃ75.98 M-19.33%
2011-12-31ยฃ94.19 M-37.63%
2010-12-31ยฃ0.15 B-13.16%
2009-12-31ยฃ0.17 B-40.78%
2008-12-31ยฃ0.29 B49.61%
2007-12-31ยฃ0.19 B76.97%
2006-12-31ยฃ0.11 B139.08%
2005-12-31ยฃ46.39 M93.42%
2004-12-31ยฃ23.98 M84.99%
2003-12-31ยฃ12.96 M34.32%
2002-12-31ยฃ9.65 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Novartis
NVS
ยฃ5.80 B 132.46%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ5.47 B 119.08%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
ยฃ6.03 B 141.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
ยฃ0.59 B-76.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
ยฃ49.37 M-98.02%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
ยฃ0.22 B-90.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ2.76 B 10.48%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
ยฃ1.20 B-51.58%๐Ÿ‡บ๐Ÿ‡ธ USA